RVMD
Sticker shock, but make it bullish
H.C. Wainwright clearly took one look at Revolution Medicines’ latest Phase 3 readout and said, “Yeah, we need a bigger number.” The firm boosted its price target on RVMD to $169 from $73, while sticking with a Buy rating.
Why the market cares
This isn’t just a random spreadsheet tweak. The higher target came after topline results from the Phase 3 RASolute 302 trial, which tested daraxonrasib against chemotherapy in second-line RAS-positive pancreatic ductal adenocarcinoma patients. That’s biotech-speak for: the drug is trying to muscle into one of the toughest cancer markets out there.
If you own the stock, the real question is whether these results make daraxonrasib look more like a legit future standard of care and less like a science-fair project with a fancy name. When analysts start lobbing around much higher targets, they’re basically saying the odds of a meaningful commercial payoff just got better.
Big picture
Biotech stocks can move on a single sentence, a single endpoint, or a single analyst with a very loud opinion. RVMD just got the kind of valuation boost that tells you Wall Street thinks the story has changed — and changed fast.